# Xtant Medical Holdings, Inc.: overview XTNT · NYSE · CIK 1453593 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/xtnt.md) · [Financials](/companies/xtnt/financials.md) · [Filings](/companies/xtnt/filings.md) · [Insiders](/companies/xtnt/insiders.md) Latest reported revenue: [$23.0m](/filings/0001493152-26-036981.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-036981). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [27.9](/filings/0001493152-25-021512.md) | [31.5 d](/filings/0001493152-26-013792.md) | [32.9](/filings/0001493152-26-022604.md) | [35.4](/filings/0001493152-26-036981.md) | [33.3](/filings/0001493152-25-021512.md) | [32.4 d](/filings/0001493152-26-013792.md) | [20.9](/filings/0001493152-26-022604.md) | [23.0](/filings/0001493152-26-036981.md) | | Gross margin | % | [58.4%](/filings/0001493152-25-021512.md) | [50.8% d](/filings/0001493152-26-013792.md) | [61.5%](/filings/0001493152-26-022604.md) | [68.6%](/filings/0001493152-26-036981.md) | [66.1%](/filings/0001493152-25-021512.md) | [54.9% d](/filings/0001493152-26-013792.md) | [57.3%](/filings/0001493152-26-022604.md) | [57.9%](/filings/0001493152-26-036981.md) | | Operating margin | % | [(13.5%)](/filings/0001493152-25-021512.md) | [(6.0%) d](/filings/0001493152-26-013792.md) | [3.2%](/filings/0001493152-26-022604.md) | [13.1%](/filings/0001493152-26-036981.md) | [7.6%](/filings/0001493152-25-021512.md) | [(2.9%) d](/filings/0001493152-26-013792.md) | [(14.0%)](/filings/0001493152-26-022604.md) | [(39.8%)](/filings/0001493152-26-036981.md) | | Net margin | % | [(18.0%)](/filings/0001493152-25-021512.md) | [(10.0%) d](/filings/0001493152-26-013792.md) | [0.2%](/filings/0001493152-26-036981.md) | [10.0%](/filings/0001493152-26-036981.md) | [3.9%](/filings/0001493152-25-021512.md) | [0.2% d](/filings/0001493152-26-013792.md) | [(14.8%)](/filings/0001493152-26-036981.md) | [(40.9%)](/filings/0001493152-26-036981.md) | | Diluted EPS | $ per share | [(0.04)](/filings/0001493152-25-021512.md) | not reported | [0.00](/filings/0001493152-26-022604.md) | [0.02](/filings/0001493152-26-036981.md) | [0.01](/filings/0001493152-25-021512.md) | not reported | [(0.02)](/filings/0001493152-26-022604.md) | [(0.07)](/filings/0001493152-26-036981.md) | | Free cash flow | $m | [(3.8) d](/filings/0001493152-25-021512.md) | [(0.0) d](/filings/0001493152-26-013792.md) | [0.1](/filings/0001493152-26-022604.md) | [0.9 d](/filings/0001493152-26-036981.md) | [4.2 d](/filings/0001493152-25-021512.md) | [5.0 d](/filings/0001493152-26-013792.md) | [(2.3)](/filings/0001493152-26-022604.md) | [(7.6) d](/filings/0001493152-26-036981.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [55.3](/filings/0001493152-23-006881.md) | [58.0](/filings/0001493152-24-012145.md) | [91.3](/filings/0001493152-25-009391.md) | [117](/filings/0001493152-26-013792.md) | [134](/filings/0001493152-26-013792.md) | | Gross margin | % | [58.8%](/filings/0001493152-23-006881.md) | [55.4%](/filings/0001493152-24-012145.md) | [60.8%](/filings/0001493152-25-009391.md) | [58.2%](/filings/0001493152-26-013792.md) | [62.9%](/filings/0001493152-26-013792.md) | | Operating margin | % | [(7.0%)](/filings/0001493152-23-006881.md) | [(11.7%)](/filings/0001493152-24-012145.md) | [(11.1%)](/filings/0001493152-25-009391.md) | [(10.3%)](/filings/0001493152-26-013792.md) | [5.4%](/filings/0001493152-26-013792.md) | | Net margin | % | [(8.8%)](/filings/0001493152-23-006881.md) | [(14.6%)](/filings/0001493152-24-012145.md) | [0.7%](/filings/0001493152-25-009391.md) | [(14.0%)](/filings/0001493152-26-013792.md) | [3.7%](/filings/0001493152-26-013792.md) | | Diluted EPS | $ per share | [(0.06)](/filings/0001493152-23-006881.md) | [(0.09)](/filings/0001493152-24-012145.md) | [0.01](/filings/0001493152-25-009391.md) | [(0.12)](/filings/0001493152-26-013792.md) | [0.03](/filings/0001493152-26-013792.md) | | Free cash flow | $m | [(1.7)](/filings/0001493152-23-006881.md) | [(7.1)](/filings/0001493152-24-012145.md) | [(11.0)](/filings/0001493152-25-009391.md) | [(16.0)](/filings/0001493152-26-013792.md) | [10.2](/filings/0001493152-26-013792.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/xtnt/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $28.8m | 68,394,000 | | Unchanged | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $28.8m | 68,394,000 | | Unchanged | | [AWM Investment Company, Inc.](/funds/1535264.md) | 2026-06-30 | $2.5m | 5,976,910 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $848.1k | 2,014,603 | | Unchanged | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $393.7k | 935,119 | | Reduced −52,291 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $217.8k | 517,133 | | Reduced −12,081 | | [Crescent Grove Advisors, LLC](/funds/1713520.md) | 2026-06-30 | $173.5k | 412,024 | | Unchanged | | [NANO CAP NEW MILLENNIUM GROWTH FUND L P](/funds/1277890.md) | 2026-06-30 | $168.4k | 400,000 | | Added +50,000 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $108.6k | 257,988 | | Unchanged | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $80.6k | 191,369 | | Added +30,358 | ## Recent filings [All 1,105 filings](/companies/xtnt/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-11 | 07:15 ET | [10-Q](/filings/0001493152-26-036981.md) | Quarterly report, period 2026-06-30 | 0001493152-26-036981 | | 2026-08-11 | 07:05 ET | [8-K](/filings/0001493152-26-036979.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-036979 | | 2026-08-07 | 16:15 ET | [8-K](/filings/0001493152-26-036586.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-036586 | | 2026-06-23 | 07:00 ET | [DEF 14A](/filings/0001493152-26-029699.md) | Proxy statement, period 2026-06-23 | 0001493152-26-029699 | | 2026-05-13 | 07:15 ET | [10-Q](/filings/0001493152-26-022604.md) | Quarterly report, period 2026-03-31 | 0001493152-26-022604 | | 2026-05-13 | 07:05 ET | [8-K](/filings/0001493152-26-022600.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-022600 | | 2026-04-13 | 09:20 ET | [8-K](/filings/0001493152-26-016308.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-016308 | | 2026-03-31 | 07:16 ET | [10-K](/filings/0001493152-26-013792.md) | Annual report, period 2025-12-31 | 0001493152-26-013792 | | 2026-03-31 | 07:05 ET | [8-K](/filings/0001493152-26-013788.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-013788 | | 2026-03-02 | 08:15 ET | [8-K](/filings/0001493152-26-008453.md) | 8.01 Other events | 0001493152-26-008453 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-013792.md), filed Mar 31, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/5cbe02c0-499f-469b-95dc-2d9724c1a8d6) ## About the filer - CIK: 1453593 - Tickers: XTNT - Exchange: NYSE - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.